Please note: The information displayed on this page might be outdated.
Triplet Therapeutics: Triplet is pursuing a transformative approach to develop treatments for repeat expansion disorders, a group of more than 40 known genetic diseases associated with expanded DNA nucleotide repeats including Huntington’s disease, myotonic dystrophy and various spinocerebellar ataxias. A significant body of human genetic evidence has identified that one central pathway, known as the DNA damage response pathway, drives onset and progression across this group of disorders. Triplet is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) development candidates to precisely knock down key components of the DDR pathway that drive repeat expansion and potentially address repeat expansion disorders en masse.
US - New England
One Kendall Square, 1400W
Cambridge, MA 02139
Cambridge, MA 02139
Company Participants at Winter Private Company Showcase
Triplet Therapeutics, CSO
Alan joined Triplet Therapeutics, Inc. as Chief Scientific Office in August 2020. Previously, he served as Chief Scientific Officer of Scholar Rock where he was responsible for research, discovery, preclinical development, and manufacturing of the company’s novel antibody-based therapeutics. Prior to joining Scholar Rock, Alan held senior level research positions in Biogen and Novartis, where he led both target validation and drug discovery efforts for multiple therapeutic modalities. Prior to Novartis, Alan served as the Chief Scientific Officer of Ardais Corporation and as Vice President of Molecular Genetics at Sequana Therapeutics/Axys Pharmaceuticals from. Prior to joining industry, Alan served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School, where his collaborative focus was on the genetics of cancer and rare diseases, including Huntington’s Disease and Myotonic Dystrophy. Alan received his A.B. in Biology from the University of Chicago, Ph.D. in Microbiology from the Boston University School of Medicine and completed his post-doctoral training at the Center for Cancer Research, Massachusetts Institute of Technology.
Triplet Therapeutics, Director, Business Development & Strategy
Amar brings life science business development and corporate strategy experience to Triplet Therapeutics, Inc. Prior to joining Triplet, Amar was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Amar advised leading biotechnology and pharmaceutical companies on strategic planning, M&A, R&D, and business development strategy. Amar received his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology, where he studied RNA engineering for therapeutic and industrial applications. His research resulted in numerous publications in peer-reviewed journals, including Nucleic Acids Research.
Eric M. Sullivan
Triplet Therapeutics, CFO
Eric Sullivan is CFO of Triplet Therapeutics, Inc. and has more than 15 years of experience working in finance and operations at life sciences companies. Before joining Triplet, he led finance at Gemini Therapeutics and Oncorus, Inc. Previously Eric served as Vice President, Finance and Treasurer at bluebird bio and held various management positions at Merrimack Pharmaceuticals and PricewaterhouseCoopers. He received his undergraduate degree in accountancy from Bentley College and is a Certified Public Accountant in Massachusetts.
Triplet Therapeutics, CMO
Dr. Irina Antonijevic serves as Chief Medical Officer at Triplet Therapeutics, She has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. Dr Antonijevic has gained experience with development of small molecules, biologics as well as nucleic acid therapeutics, in a number of global pharma and biotech organizations in the US and Europe. Before joining Triplet Therapeutics, Inc., she was VP of Translational Medicine and Development at Wave Life Sciences in Cambridge, MA, developing stereopure nucleic acid therapeutics for rare genetic diseases.Dr Antonijevic has an MD from the Technical University, Munich (Germany), and a PhD in neurophysiology from the University of Edinburgh, UK. She trained in psychiatry and neurology at the Max Planck Institute of Psychiatry (in Munich), and is board certified in Germany.She obtained her venia legendi at the Charite, Berlin University in 2004; she is a reviewer for the German Ministry of Research and member of two supervisory boards in Germany: 4SC AG since 2012, and Paion AG since 2017.
Triplet Therapeutics, Chief Executive Officer
Dr. Nessan Bermingham is a Co-Founder of Triplet Therapeutics and serves as its Chief Executive Officer, Board Member & President. He also serves as Advisor at Atlas Venture. He served as Board Member at Xilio Therapeutics. He is a Co-Founder of Intellia Therapeutics, where he served as President and Chief Executive Officer. He served as Board Observer at Lysosomal Therapeutics. He brings more than a decade's experience in life sciences investing across venture, public and secondary markets. His keen entrepreneurial vision inspired him to found Intellia. he has successfully co-founded numerous healthcare and biotech startup companies, including Ascelegen and Tal Medical. Prior to joining Atlas, he was a managing partner at Omega Funds and founder of Bio Equity Capital, a healthcare-focused special situations firm. He received his Ph.D. in Molecular Biology from Imperial College London, was a Howard Hughes Associate Fellow at Baylor College of Medicine and received his B.S. from Queen's University Belfast.